Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel Authors: Bosco Paes, Vivien Brown, Erin Courtney, Erin Fleischer, Fiona Guy, Eddy Lau, Allan Mills, Julie Toole, Meagan Bardan, Cynthia Wong, Gary Lam, Graeme N. Smith Published: 2024 ABSTRACT ABSTRACTIn June 2024, a group of 12 experts in the respiratory syncytial virus (RSV) field representing a cross-section of healthcare provider types who treat and care for pregnant individuals and infants, assembled to discuss the implementation of a broad infant prophylaxis program with nirsevimab in Ontario. To gain insight on potential best practices founded on the experiences of other jurisdictions, the meeting comprised a review of the 2023/2024 RSV season programs in Spain, France, and the United States that implemented nirsevimab prophylaxis. The impact of nirsevimab in reducing severe RSV disease among infants during the first RSV season was assessed including the implications on hospital resources and healthcare system costs. The panel also reviewed the results of a 2024 online survey of healthcare providers in the province to gain insight into how the program should be implemented in Ontario to facilitate uptake in infants born during and before the onset of the RSV season. The resulting discussion led to panel consensus on several recommendations to help inform programmatic decisions regarding how nirsevimab should be administered to infants in Ontario to achieve optimal uptake and best protection against this potentially devastating infectious disease. Introduction Respiratory syncytial virus (RSV) is a highly contagious pathogen, infecting most children before two years of age.1 Although RSV typically manifests as an upper respiratory tract infection (URTI), approximately 40% of cases progress to lower respiratory tract illness (LRTI) such as bronchiolitis and pneumonia.1 Due to its high prevalence and potential severity, it is unsurprising that RSV is the leading cause of hospitalization in children younger than two years in Canada.2 Hospitalization may require invasive respiratory support and intensive care unit (ICU) stay with substantial hospital resource use and costs to the healthcare system.3–5 Healthcare resource utilization is equally significant for non-hospitalized children, encompassing visits to primary healthcare professionals (HCPs), pediatricians, and emergency rooms.5 Secondary costs associated with RSV involve productivity losses and out-of-pocket expenses incurred by parents and caregivers of ill children.6–8 Preterm infants and those with specific comorbidities are at highest risk for severe infection during their first RSV season.9 However, 80% of children hospitalized with RSV are born at term and otherwise healthy with no underlying medical conditions.10 Long-term consequences of RSV can be associated with respiratory sequelae, such as recurrent wheezing and asthma,11,12 further contributing to an overall burden of illness that strongly predicates a need to protect all infants against RSV infection. Until recently, RSV prevention in young children was limited to palivizumab (PVZ), a monoclonal antibody that requires monthly dosing during the RSV season. Due to stringent eligibility criteria, less than 2% of all Canadian infants (i.e., high-risk) qualified for prophylaxis.13–15 While PVZ reduces the risk of RSV hospitalization in high-risk infants by 38–86% compared to placebo,16,17 it is not uniformly cost-effective for widespread use.18 In 2023, nirsevimab, an extended half-life, human monoclonal antibody was approved in Canada.19,20 A meta-analysis confirmed an 80% reduction in medically-attended RSV infection (MARI) and an 81% reduction in RSV hospitalizations in healthy preterm and term infants compared to placebo.21–23 A single dose of nirsevimab offers protection for the total duration of the RSV season (typically November to March in the Northern hemisphere).24,25 In Canada, nirsevimab is uniquely indicated for the prevention of RSV LRTI in all infants entering their first RSV season irrespective of risk status, and children <2 years at high-risk for severe RSV disease in their second season.20 In December 2023, Health Canada approved the administration of a maternal RSV vaccine (RSVpreF) between 32–36 weeks gestation for the prevention of RSV LRTI in infants.26 Based on the approved dosing interval, RSVpreF prevents 57.3% and 48.2% of MARI and RSV hospitalizations, respectively, through the first 180 days of life.27 In March 2024, Canada’s National Advisory Committee on Immunization (NACI) recommended that Canadian provinces and territories preferentially build toward a universal RSV immunization program with nirsevimab due to its higher efficacy and possible longer duration of protection. If parents choose not to administer nirsevimab to an infant, RSVpreF may be considered.22 In May 2024, Quebec became the first Canadian province to announce a government-funded universal RSV prophylaxis program with nirsevimab for infants.28 At that time, all other provinces and territories remained undecided on whether to implement similar programs for the 2024/2025 season. Ontario RSV expert panel Unlike vaccines, there is no Canadian precedent on how nirsevimab should be delivered to the public through a universal program. Choosing the best implementation framework is key to promoting uptake and achieving the greatest reduction in RSV illness. In June 2024, Sanofi invited a panel of 12 HCPs spanning diverse provider types (obstetricians, midwives, family physicians, pediatricians, hospital pharmacists, pediatric and public health nurses, emergency room physicians, infectious disease specialists) to assemble, with the principal objective of developing recommendations to support a universal program with nirsevimab for infants in Ontario. The panel conferred on (i) the early experiences of countries that have already implemented RSV prophylaxis programs utilizing nirsevimab, and (ii) the provincial results of a Canadian HCP survey to understand their perceptions of optimizing a nirsevimab program. In July 2024, the Government of Ontario announced funding for a provincial all-infant RSV prophylaxis program with nirsevimab.29 To support decision-making around the logistics of this program, as well as implementation in other Canadian provinces and international locales, a summary of the panel meeting is presented below. Section I: Early international experiences with nirsevimab programs for infant RSV prophylaxis During the 2023/2024 RSV season, several countries initiated universal RSV prophylaxis programs with nirsevimab (Table 1). Implementation comprised public education messaging, HCP training, and sites/healthcare workflow for nirsevimab administration for infants born during the RSV season and before the season onset (catch-up cohort). Data were collected by national and regional surveillance systems to evaluate nirsevimab’s impact in these jurisdictions. Ontario’s RSV Expert Panelists discussed campaigns in the United States, Spain, and France to better understand successes and challenges, and apply initial best practices toward provincial recommendations. Each country offered hospital-based administration of nirsevimab for infants born during the RSV season, with country-dependent eligibility. In Spain, the catch-up program was also hospital-based, while infants in the United States and France typically received nirsevimab through their primary HCP.Table 1.Healthcare resource utilization for RSV prophylaxis with nirsevimab in countries during the 2023-2024 season. United StatesSpainFranceNirsevimab approvalJuly 202330October 202231October 202231Nirsevimab product availableSingle intramuscular dose from a pre-filled syringe of nirsevimab of 50 or 100 mg in the thigh or deltoid muscle, depending on the infant’s weightTiming of nirsevimab campaignOctober 1, 2023 to March 31, 2024 in most continental states32September 25, 2023 to March 31, 2024**33Sept 15, 2023 to March 202434Eligibility CiteriaSeasonal: Infants born between October 1, 2023 and March 31, 2024*Catch-up: Infants <8 months on October 1, 2023*High-risk: Infants and children aged 8–19 months at increased risk for severe RSV disease and entering their second RSV season35Seasonal: Infants born between September 25, 2023 and March 31, 2024Catch-up: Infants <6 months old born between April 1 and September 24, 2023High-risk: Infants and children 6–24 months of age on September 25, 2023 at increased risk for severe RSV disease36Seasonal: Infants born between September 15, 2023 and March 2024Catch-up: Infants born between February 6 and September 14, 202337Promotion:-Coordinated educational campaign for parents and providers between CDC, AAP, and other professional societies35-Education and communication campaign run by government: in-person and online meetings with HCPs, in-person and online meetings with hospital coordinating teams for nirsevimab programs, text-message to parents of non-immunized infants with FAQs, and testimony of parents of children with RSV- A series of webinars from Public Health available on YouTube about RSV, nirsevimab, and access information-Unified supportive messaging from scientific & medical societies, policy makers and public health experts38,39−Education and communication campaign run by governmentCoverage-Infants and children eligible for Medicaid and those underinsured are covered through the VFC program; infants and children may also be covered through private insurance40,41-Government centralized purchase (free of charge for parents)33-Government centralized purchase (free of charge for parents)42Delivery:Seasonal: Administered in hospital (if hospital is part of VFC program), or in a community setting post-dischargeHigh-risk and catch-up: Administered by primary HCP; those without a HCP (or who would likely age out of eligibility prior to the provider receiving nirsevimab supply) received nirsevimab in some hospitals43Seasonal: Administered in hospitalHigh-risk and catch-up: Flexible administration appointments were electronically scheduled for timeslots in a three-week campaign between 10am to 7pm daily, including over weekends. Missed appointments were rescheduled for a hospital appointment if during the three-week campaign, and to their primary care pediatrician for administration, if the hospital campaign had ended.33Seasonal: In hospital, nirsevimab prescription was from physician or midwife, then filled at the hospital pharmacy, and administered to newborn by doctor, midwife or nurse. If in-hospital administration did not occur, there was opportunity for community administration.Catch-up: Nirsevimab prescription was from physician or midwife, nirsevimab was dispensed from community pharmacy, and administered to newborn by doctor, midwife or nurse at primary healthcare center.42Nirsevimab uptake rates:43% 44***79-97%38,46–49Not yet published (parental acceptance was measured to be 60-80%)50Adverse event surveillance and reporting:Adverse events that happened after nirsevimab administration were reported to the FDA’s MedWatch Adverse Event Reporting Program.If an adverse event occurred while co-administering nirsevimab with a vaccine, it was reported to the Vaccine Adverse Event Reporting System.51Galicia has an adverse event surveillance system:- routine post-immunization surveillance− active surveillance of preterm infants for any adverse event or hospitalization in the first three weeks since nirsevimab administrationNo AEs reported after 7,241 administered doses of nirsevimab33 (no updated data) Nirsevimab effectiveness against MA RSV77% (RSV-associated emergency room-department visits)4589% (RSV-MARI episodes)45 Nirsevimab effectiveness against RSV hospitalization91-98%4570-89%47–49,52,5383% (RSV-associated bronchiolitis in infants younger than 12 months of age)54Nirsevimab effectiveness against ICU admission 86-92% (ICU admissions)48,5376-81% (bronchiolitis leading to ICU admission)3470% (RSV-associated bronchiolitis leading to PICU admission in younger than 12 months)5467% (RSV-associated bronchiolitis resulting in ventilatory support)54Abbreviations: AAP = American Academy of Pediatrics, AE = adverse events, CDC = Centers of Disease Control and Prevention, FAQ = Frequently Asked Questions, FDA = Food and Drug Administration, HCP = Healthcare Professional, ICU = Intensive Care Unit, MARI = Medically Attended RSV Infection, RSV = Respiratory Syncytial Virus, VFC = Vaccines for Children.*In September 2023, the maternal RSV vaccine also became available to prevent RSV disease in young infants in the United States, with the American Advisory Committee on Immunization Practices (ACIP) recommending either nirsevimab or maternal RSV vaccination to protect infants born during or entering their first RSV season. Nirsevimab is not needed for most infants aged <8 months whose mother received RSVpreF vaccine ≥14 days before birth.32,35**Spain comprises 17 communities and two autonomous cities, and each made its own decisions about their campaign duration. Sept 25, 2023 was one of the earliest campaigns start dates selected.***Doses were only available for approximately 40% of the birth cohort. Table 1.Healthcare resource utilization for RSV prophylaxis with nirsevimab in countries during the 2023-2024 season. United StatesSpainFranceNirsevimab approvalJuly 202330October 202231October 202231Nirsevimab product availableSingle intramuscular dose from a pre-filled syringe of nirsevimab of 50 or 100 mg in the thigh or deltoid muscle, depending on the infant’s weightTiming of nirsevimab campaignOctober 1, 2023 to March 31, 2024 in most continental states32September 25, 2023 to March 31, 2024**33Sept 15, 2023 to March 202434Eligibility CiteriaSeasonal: Infants born between October 1, 2023 and March 31, 2024*Catch-up: Infants <8 months on October 1, 2023*High-risk: Infants and children aged 8–19 months at increased risk for severe RSV disease and entering their second RSV season35Seasonal: Infants born between September 25, 2023 and March 31, 2024Catch-up: Infants <6 months old born between April 1 and September 24, 2023High-risk: Infants and children 6–24 months of age on September 25, 2023 at increased risk for severe RSV disease36Seasonal: Infants born between September 15, 2023 and March 2024Catch-up: Infants born between February 6 and September 14, 202337Promotion:-Coordinated educational campaign for parents and providers between CDC, AAP, and other professional societies35-Education and communication campaign run by government: in-person and online meetings with HCPs, in-person and online meetings with hospital coordinating teams for nirsevimab programs, text-message to parents of non-immunized infants with FAQs, and testimony of parents of children with RSV- A series of webinars from Public Health available on YouTube about RSV, nirsevimab, and access information-Unified supportive messaging from scientific & medical societies, policy makers and public health experts38,39−Education and communication campaign run by governmentCoverage-Infants and children eligible for Medicaid and those underinsured are covered through the VFC program; infants and children may also be covered through private insurance40,41-Government centralized purchase (free of charge for parents)33-Government centralized purchase (free of charge for parents)42Delivery:Seasonal: Administered in hospital (if hospital is part of VFC program), or in a community setting post-dischargeHigh-risk and catch-up: Administered by primary HCP; those without a HCP (or who would likely age out of eligibility prior to the provider receiving nirsevimab supply) received nirsevimab in some hospitals43Seasonal: Administered in hospitalHigh-risk and catch-up: Flexible administration appointments were electronically scheduled for timeslots in a three-week campaign between 10am to 7pm daily, including over weekends. Missed appointments were rescheduled for a hospital appointment if during the three-week campaign, and to their primary care pediatrician for administration, if the hospital campaign had ended.33Seasonal: In hospital, nirsevimab prescription was from physician or midwife, then filled at the hospital pharmacy, and administered to newborn by doctor, midwife or nurse. If in-hospital administration did not occur, there was opportunity for community administration.Catch-up: Nirsevimab prescription was from physician or midwife, nirsevimab was dispensed from community pharmacy, and administered to newborn by doctor, midwife or nurse at primary healthcare center.42Nirsevimab uptake rates:43% 44***79-97%38,46–49Not yet published (parental acceptance was measured to be 60-80%)50Adverse event surveillance and reporting:Adverse events that happened after nirsevimab administration were reported to the FDA’s MedWatch Adverse Event Reporting Program.If an adverse event occurred while co-administering nirsevimab with a vaccine, it was reported to the Vaccine Adverse Event Reporting System.51Galicia has an adverse event surveillance system:- routine post-immunization surveillance− active surveillance of preterm infants for any adverse event or hospitalization in the first three weeks since nirsevimab administrationNo AEs reported after 7,241 administered doses of nirsevimab33 (no updated data) Nirsevimab effectiveness against MA RSV77% (RSV-associated emergency room-department visits)4589% (RSV-MARI episodes)45 Nirsevimab effectiveness against RSV hospitalization91-98%4570-89%47–49,52,5383% (RSV-associated bronchiolitis in infants younger than 12 months of age)54Nirsevimab effectiveness against ICU admission 86-92% (ICU admissions)48,5376-81% (bronchiolitis leading to ICU admission)3470% (RSV-associated bronchiolitis leading to PICU admission in younger than 12 months)5467% (RSV-associated bronchiolitis resulting in ventilatory support)54Abbreviations: AAP = American Academy of Pediatrics, AE = adverse events, CDC = Centers of Disease Control and Prevention, FAQ = Frequently Asked Questions, FDA = Food and Drug Administration, HCP = Healthcare Professional, ICU = Intensive Care Unit, MARI = Medically Attended RSV Infection, RSV = Respiratory Syncytial Virus, VFC = Vaccines for Children.*In September 2023, the maternal RSV vaccine also became available to prevent RSV disease in young infants in the United States, with the American Advisory Committee on Immunization Practices (ACIP) recommending either nirsevimab or maternal RSV vaccination to protect infants born during or entering their first RSV season. Nirsevimab is not needed for most infants aged <8 months whose mother received RSVpreF vaccine ≥14 days before birth.32,35**Spain comprises 17 communities and two autonomous cities, and each made its own decisions about their campaign duration. Sept 25, 2023 was one of the earliest campaigns start dates selected.***Doses were only available for approximately 40% of the birth cohort. Healthcare resource utilization for RSV prophylaxis with nirsevimab in countries during the 2023-2024 season. Abbreviations: AAP = American Academy of Pediatrics, AE = adverse events, CDC = Centers of Disease Control and Prevention, FAQ = Frequently Asked Questions, FDA = Food and Drug Administration, HCP = Healthcare Professional, ICU = Intensive Care Unit, MARI = Medically Attended RSV Infection, RSV = Respiratory Syncytial Virus, VFC = Vaccines for Children. *In September 2023, the maternal RSV vaccine also became available to prevent RSV disease in young infants in the United States, with the American Advisory Committee on Immunization Practices (ACIP) recommending either nirsevimab or maternal RSV vaccination to protect infants born during or entering their first RSV season. Nirsevimab is not needed for most infants aged <8 months whose mother received RSVpreF vaccine ≥14 days before birth.32,35 **Spain comprises 17 communities and two autonomous cities, and each made its own decisions about their campaign duration. Sept 25, 2023 was one of the earliest campaigns start dates selected. ***Doses were only available for approximately 40% of the birth cohort. Requisite time for program planning In Spain, there was rapid progression from nirsevimab approval to its recommendation by the National Immunization Technical Advisory Groups for an all-infant program.38 Within months, Spanish jurisdictions announced their universal programs, and medical societies publicly endorsed nirsevimab use. Program planning focused on implementation that would be feasible for HCPs and hospitals, while quickly achieving high uptake (79–97%).38,46–49 The precedent for mass childhood immunization in a hospital environment was previously set with Spain’s universal pediatric influenza immunization campaign,38 which was easily adopted for nirsevimab. Conversely, the United States had a very short timeline from nirsevimab approval to implementation of their universal all-infant program, allowing limited opportunity for engagement with key HCPs to ensure they were aware of new product recommendations to initiate procurement processes. Additionally, given that private insurance companies in the US have 12 months to adopt the endorsed American Advisory Committee on Immunization Practices vaccine recommendations, there was considerable uncertainty around whether parents would opt for nirsevimab for infants in their first RSV season. Implementation lessons The panel discussed experiences from these countries including the risks and benefits of considering nirsevimab under the vaccine umbrella to capitalize on existing vaccination pathways. A robust education campaign for both HCPs and the public was recognized as a critical factor for high acceptance in the initial year of a universal program as evident in both Spain and France.38,54 This should factor into program planning to ensure that messaging around the receipt of nirsevimab aligns with both medication availability and ease of access, to maintain HCP and parental trust. Finally, employing a hospital-based administration program prior to discharging infants born during the RSV season appeared optimal for providing timely RSV protection. Overall, the key to success relies on an uncomplicated program for HCPs to consistently communicate and implement, and for parents to understand and access. Section II: Panel discussion on the results of the HCP survey for nirsevimab implementation in Ontario and optimal processes for a successful program In March 2024, a survey was conducted of Canadian HCPs to understand their opinions on optimal practices for the implementation of an all-infant RSV prophylaxis program with nirsevimab. Survey methodology The survey comprised 23 multiple choice and open-ended questions about public education strategies on RSV and nirsevimab, and the optimal time and setting to deliver nirsevimab to infants born during the RSV season and in the catch-up period. The survey was electronically disseminated by MD Analytics, a Canadian market research firm with an online polling panel comprising 24,000 Canadian HCPs, each manually validated against their respective provincial regulatory bodies.55 Eligible respondents were those who provide antenatal care and treat children (obstetricians, family physicians, pediatricians, public health and hospital nurses, emergency room physicians, infectious disease specialists, and hospital pharmacists; midwives are not part of the panel). The e-mail survey was sent to a random sample of members from each provider type, based on pre-determined quotas. Two reminders were sent to non-respondents, prior to engaging additional panel members. The targeted 250 sample size was achieved, and respondents were reimbursed for survey completion. The results from Ontario respondents (n = 106) were presented to the Ontario RSV Expert Panel to inform discussion; selected panel comments are outlined in Supplementary File (S1). Survey results and panel discussion i) Survey respondent demographics Of the respondents, 42.5% were female (mean age; 47.5 years; Table 2), and 62.2% were aged <50 years (Figure 1). Most were primary HCPs (39.6% family physicians; 17.0% community pediatricians). Figure 1.Age of Ontario survey respondents (n = 106).Table 2.Demographics of Ontario healthcare professionals that completed the survey for nirsevimab implementation (n = 106). n (%)Mean age, years ± SD47.5 ± 11.4Median age, years (range)45 (31 – 90)Female61 (57.5)Male45 (42.5)Healthcare provider typeFamily physician42 (39.6)Pediatrician22 (20.8)Hospital4 (18.2)Community9 (40.9)Hospital + community9 (40.9)Obstetricians14 (13.2)Emergency room physician9 (8.5)Infectious disease specialist2 (1.9)Pediatric1 (50.0)Non-pediatric1 (50.0)Nurse13 (12.3)Pediatrics1 (7.7)Labour & delivery3 (23.1)Public health3 (23.1)Other nursing role treating children > 50% of time6 (46.1)Hospital pharmacist4 (3.8)Drug utilization2 (50.0)Non-drug utilization2 (50.0) Age of Ontario survey respondents (n = 106). Table 2.Demographics of Ontario healthcare professionals that completed the survey for nirsevimab implementation (n = 106). n (%)Mean age, years ± SD47.5 ± 11.4Median age, years (range)45 (31 – 90)Female61 (57.5)Male45 (42.5)Healthcare provider typeFamily physician42 (39.6)Pediatrician22 (20.8)Hospital4 (18.2)Community9 (40.9)Hospital + community9 (40.9)Obstetricians14 (13.2)Emergency room physician9 (8.5)Infectious disease specialist2 (1.9)Pediatric1 (50.0)Non-pediatric1 (50.0)Nurse13 (12.3)Pediatrics1 (7.7)Labour & delivery3 (23.1)Public health3 (23.1)Other nursing role treating children > 50% of time6 (46.1)Hospital pharmacist4 (3.8)Drug utilization2 (50.0)Non-drug utilization2 (50.0) Demographics of Ontario healthcare professionals that completed the survey for nirsevimab implementation (n = 106). ii) Parental education about RSV and nirsevimab Primary HCPs (family physicians and pediatricians, 91.5% each), followed by hospital staff (60.4%) and obstetricians (50.9%) were considered most responsible for educating parents about RSV and nirsevimab (Supplementary File [S2]). The panel agreed that while primary HCPs have a role in educating parents, the responsibility should be shared by all HCPs who have interactions with pregnant individuals, parents, and infants. Discussions about RSV prevention and nirsevimab should include differences between passive (maternal RSV vaccine administration or infant RSV monoclonal antibody administration) and active immunization, and should occur throughout pregnancy to ensure that parental questions are addressed prior to delivery. The panel emphasized that the success of a universal program relies heavily on parental education and underscores the need to document in the patient’s medical record that these conversations have occurred and that parents accept their child’s receipt of nirsevimab. iii) Optimal time and setting for administration of nirsevimab to infants born during the RSV season Of respondents, 74.6% reported that infants should receive nirsevimab prior to hospital discharge, while the remainder opted for administration by the infant’s primary HCP, 48–72 hours after discharge (Supplementary File [S3]). Nearly 30% of respondents agreed that both obtaining consent and administering nirsevimab should be the responsibility of the discharge provider, while the remainder reported that both tasks should be performed by other HCPs (e.g., pediatrician, postpartum nurse; Supplementary File [S4]). The panel concluded that for infants born during the RSV season, receiving nirsevimab before hospital discharge was most favorable for (i) optimizing uptake, (ii) reducing the risk of community-acquired RSV, and (iii) avoiding loss to follow-up. However, the optimal time for administration (immediately after birth, on the Mother Baby Unit, or just prior to discharge home) should be an institution-level decision. Each hospital should create an order-set with a Yes/No checkbox for receipt of nirsevimab and verbal consent documentation, similar to other interventions administered to infants (e.g., Vitamin K). iv) Follow-up for infants who did not receive nirsevimab in hospital Among the respondents, 52.8% felt that infants born before the RSV season should receive nirsevimab during scheduled primary care appointments for other childhood vaccines (co-administered), while 36.8% believed that nirsevimab administration should be scheduled separately (Supplementary File [S5]). For infants born during the RSV season who did not receive nirsevimab prior to hospital discharge, respondents most commonly chose family physicians (93.4%), pediatricians (76.4%), and public health nurses (34.0%) as providers to counsel parents and schedule administration (Supplementary File [S6]). While the panel agreed that the primary care setting was ideal for nirsevimab administration, 20% of Ontarians are without a primary HCP.56 Since infrastructure currently exists to conduct mass immunization clinics, Public Health is well-positioned to address the gap for these infants as well as those born before the RSV season. Parents should be provided handouts at hospital discharge with information about clinic schedules and locations. Hospital-based immunization clinics for catch-up infants have been successful in other countries, and the panel opined this was suitable for targeted groups of high-risk infants and may be possible for all infants if implemented in adequately resourced hospitals. v) Optimal start date of nirsevimab immunization campaign Most respondents (65.2%) were not comfortable with infants receiving nirsevimab >4 weeks prior to the season’s predicted start and 29.2% felt that anytime within the month prior to the RSV season was appropriate (Supplementary File [S7]). The panel expressed that immunization commencement should strike a balance between capturing the greatest number of infants, while protecting infants throughout the season, acknowledging that nirsevimab protection likely extends beyond five months.25,57 vi) Panel discussion around enablers of program success The panel described several facilitators to ensure a successful nirsevimab campaign based on uptake, outcomes, and parental and HCP satisfaction. Public education about RSV and nirsevimab Anticipating that both the public and parents of infants will require information about RSV and evidence for the safety and effectiveness of nirsevimab, the panel discussed broad provincial promotion plans. A public education campaign preceding the RSV season was considered paramount, with consistent and simple messaging strongly supported by national associations including the Canadian Pediatric Society (CPS), Society of Obstetricians and Gynecologists of Canada (SOGC), College of Family Physicians of Canada (CFPC), and Immunize Canada. Highlighting the NACI recommendations is important, since both RSVpreF and nirsevimab will be available in Ontario in the upcoming season. Regardless of whether parents select the maternal vaccine or infant immunization for RSV protection, both have demonstrated efficacy and safety. However, NACI recommends nirsevimab over RSVpreF due to both the antibody’s high efficacy, and possible longer duration of protection.21 Infants born during the RSV season and catch-up period will have different nirsevimab administration settings, which is a potential source of confusion and uncertainty for parents. Proper framing of the seasonal program is needed to limit confusion. Similar to influenza and COVID vaccination campaigns, messaging should focus on when the dose should ideally be administered to infants and at which locations; Spain achieved high nirsevimab uptake with similar messaging from government and HCPs. During the 2023/2024 RSV season, some countries highlighted the impact of nirsevimab against bronchiolitis, rather than RSV specifically,58 due to public awareness of the former. In France, nirsevimab was publicly introduced as a “preventative treatment” to facilitate acceptance by parents of young children.59 However, in Spain, nirsevimab was aligned with vaccines, to capitalize on high vaccine acceptance and public familiarity with the vaccination process.38 The panel suggested that, in Ontario, framing nirsevimab as a protective antibody, similar to Rho(D) immune globulin for pregnant women, may facilitate acceptance. Tracking receipt of nirsevimab The panel highlighted the vital need for a centralized provincial database accessible to all HCPs to track receipt of nirsevimab in addition to vaccines. Given the absence of such a system, the panel discussed the value of new and existing electronic options of record-keeping, such as BORN (Ontario’s Pregnancy, Birth and Childhood Registry and Network), and identified HCP awareness of and access to such databases as potential challenges. They emphasized that paper-based documentation might be necessary until a more viable electronic database becomes available and accessible to all HCPs. For infants born during RSV season, if nirsevimab is part of a standard order, an HCP would sign off that it had been administered and include this in the infant’s discharge record. Additionally, nirsevimab receipt should be documented in the child’s yellow personal immunization card (used in Ontario) with a reminder to present it to their child’s primary HCP, along with the hospital discharge summary. For infants born before the RSV season, an accessible electronic system is necessary to ensure that children – particularly those without a primary HCP – can be efficiently identified, contacted, and administered nirsevimab. Electronic methods of flagging those eligible in the upcoming season and sending out letters, e-mails or text reminders to parents is strongly encouraged. Need for program monitoring and assessment Infrastructure will be required to collect and share data on immunization status between HCPs, hospitals, and research organizations in Ontario. This will actively facilitate program planning, nirsevimab delivery, RSV surveillance, inform health policy in future RSV seasons, and permit short- and long-term safety monitoring of nirsevimab. Across Canada, surveillance exists to capture burden reduction data for influenza, COVID, and RSV. However, as with all new preventative interventions, the provincial government should pursue linkages between public health, hospital, laboratory, and other healthcare resource utilization databases to optimally assess nirsevimab’s impact. The panel supported the use of new billing codes to track nirsevimab utilization for both those aged <1 year and 12–24 months, to conduct outcomes related research. Integrating midwives into the nirsevimab delivery workflow In 2021/2022, 20% of provincial births were attended by midwives.60 As per their scope of practice, Ontario midwives can administer RSVpreF vaccine but not nirsevimab, unlike in France.61 For hospital births, the panel stated that standing orders from family doctors, pediatricians or hospital-based medical directives would provide appropriate delegation of authority to overcome this hurdle. Additionally, midwives typically conduct home visits within 24–48 hours of the infant’s birth, providing an opportunity to administer nirsevimab if future scope evolves to include nirsevimab. For babies born outside the hospital setting, hospital directives would not apply, and midwives must be aware of nirsevimab access points to inform new parents. Storage and handling of nirsevimab Nirsevimab could be housed in hospital pharmacies or refrigerated in appropriate hospital administration sites provided cold chain requirements are met. Hospitals and community HCPs would ideally order product on a weekly basis, to minimize required storage space. Additionally, any healthcare setting receiving nirsevimab stock will require a monitored medication refrigerator that has been approved by the local Public Health Unit. Indigenous communities The panel noted that optimal nirsevimab administration workflow may differ in Indigenous community settings, and that collaboration between these communities and Public Health may aid in successful program implementation. Historically, the delivery of palivizumab in Northern and remote communities was managed by primary HCPs. Based on the logistical challenges in these regions, a similar process could be adopted for the bulk delivery of nirsevimab, given its 24-month shelf-life. Conclusions This panel meeting comprised Ontario HCP experts in the RSV field who discussed best practices for a universal infant prophylaxis program with nirsevimab. The panel reached consensus on several recommendations (Table 3) for the successful implementation of the new long-acting monoclonal antibody through a provincial program that – as has been observed through real-world evidence from Europe and the United States – is expected to significantly reduce the overall burden of RSV illness in infants in Ontario, if streamlined efficiently with high uptake.Table 3.Ontario RSV Expert Panel recommendations.The public education and promotional campaign to increase awareness about RSV and nirsevimab should involve consistent and unified messaging from the Ontario Ministry of Health, local public health units, and relevant medical associations and societies. The information campaign should be ongoing year-round, with amplification to the public in the 4-6 weeks prior to the start of the immunization program.All HCPs should be both responsible for and opportunistic about educating parents about RSV and nirsevimab, from early pregnancy onwards.Nirsevimab immunization should begin approximately four weeks prior to the predicted start of the RSV season to achieve optimal uptake while protecting infants for the duration of the season.For babies born during the RSV season, nirsevimab administration should occur in hospital at a time (i.e., immediately after birth, in the Mother-Baby Unit, or at discharge) decided on at an institution-level.Parents of infants who received nirsevimab in hospital should be given two records of its administration (discharge summary + yellow card) to present to their primary HCP, with counseling from hospital providers on the importance of sharing these documents with the primary HCP. (Note: There is currently a significant lack of a practical and accurate immunization record system in Ontario, and the panel agreed that this should be a priority initiative for the province. The use of discharge summary + yellow card is a short-term recommendation for the upcoming season, and should be replaced by an electronic means of capturing nirsevimab administration data in Ontario to facilitate the tracking of both infants born during RSV season and before RSV season.)For both infants who leave the hospital without receiving nirsevimab, and those born before the RSV season, primary HCPs should be most responsible for making certain that they have an opportunity to receive nirsevimab; local Public Health Units are well suited to make certain that those who do not have a primary HCP can receive nirsevimab, through immunization clinics.Policies and protocols should be developed to ensure that regardless of the birth setting or labor and delivery provider, every infant has efficient, equitable access to nirsevimab administration, and that available access routes have been clearly communicated to parents.Abbreviations: HCP = Healthcare Professional, RSV = Respiratory Syncytial Virus. Table 3.Ontario RSV Expert Panel recommendations.The public education and promotional campaign to increase awareness about RSV and nirsevimab should involve consistent and unified messaging from the Ontario Ministry of Health, local public health units, and relevant medical associations and societies. The information campaign should be ongoing year-round, with amplification to the public in the 4-6 weeks prior to the start of the immunization program.All HCPs should be both responsible for and opportunistic about educating parents about RSV and nirsevimab, from early pregnancy onwards.Nirsevimab immunization should begin approximately four weeks prior to the predicted start of the RSV season to achieve optimal uptake while protecting infants for the duration of the season.For babies born during the RSV season, nirsevimab administration should occur in hospital at a time (i.e., immediately after birth, in the Mother-Baby Unit, or at discharge) decided on at an institution-level.Parents of infants who received nirsevimab in hospital should be given two records of its administration (discharge summary + yellow card) to present to their primary HCP, with counseling from hospital providers on the importance of sharing these documents with the primary HCP. (Note: There is currently a significant lack of a practical and accurate immunization record system in Ontario, and the panel agreed that this should be a priority initiative for the province. The use of discharge summary + yellow card is a short-term recommendation for the upcoming season, and should be replaced by an electronic means of capturing nirsevimab administration data in Ontario to facilitate the tracking of both infants born during RSV season and before RSV season.)For both infants who leave the hospital without receiving nirsevimab, and those born before the RSV season, primary HCPs should be most responsible for making certain that they have an opportunity to receive nirsevimab; local Public Health Units are well suited to make certain that those who do not have a primary HCP can receive nirsevimab, through immunization clinics.Policies and protocols should be developed to ensure that regardless of the birth setting or labor and delivery provider, every infant has efficient, equitable access to nirsevimab administration, and that available access routes have been clearly communicated to parents.Abbreviations: HCP = Healthcare Professional, RSV = Respiratory Syncytial Virus. Ontario RSV Expert Panel recommendations. The public education and promotional campaign to increase awareness about RSV and nirsevimab should involve consistent and unified messaging from the Ontario Ministry of Health, local public health units, and relevant medical associations and societies. The information campaign should be ongoing year-round, with amplification to the public in the 4-6 weeks prior to the start of the immunization program. The public education and promotional campaign to increase awareness about RSV and nirsevimab should involve consistent and unified messaging from the Ontario Ministry of Health, local public health units, and relevant medical associations and societies. The information campaign should be ongoing year-round, with amplification to the public in the 4-6 weeks prior to the start of the immunization program. All HCPs should be both responsible for and opportunistic about educating parents about RSV and nirsevimab, from early pregnancy onwards. All HCPs should be both responsible for and opportunistic about educating parents about RSV and nirsevimab, from early pregnancy onwards. Nirsevimab immunization should begin approximately four weeks prior to the predicted start of the RSV season to achieve optimal uptake while protecting infants for the duration of the season. Nirsevimab immunization should begin approximately four weeks prior to the predicted start of the RSV season to achieve optimal uptake while protecting infants for the duration of the season. For babies born during the RSV season, nirsevimab administration should occur in hospital at a time (i.e., immediately after birth, in the Mother-Baby Unit, or at discharge) decided on at an institution-level. For babies born during the RSV season, nirsevimab administration should occur in hospital at a time (i.e., immediately after birth, in the Mother-Baby Unit, or at discharge) decided on at an institution-level. Parents of infants who received nirsevimab in hospital should be given two records of its administration (discharge summary + yellow card) to present to their primary HCP, with counseling from hospital providers on the importance of sharing these documents with the primary HCP. (Note: There is currently a significant lack of a practical and accurate immunization record system in Ontario, and the panel agreed that this should be a priority initiative for the province. The use of discharge summary + yellow card is a short-term recommendation for the upcoming season, and should be replaced by an electronic means of capturing nirsevimab administration data in Ontario to facilitate the tracking of both infants born during RSV season and before RSV season.) Parents of infants who received nirsevimab in hospital should be given two records of its administration (discharge summary + yellow card) to present to their primary HCP, with counseling from hospital providers on the importance of sharing these documents with the primary HCP. (Note: There is currently a significant lack of a practical and accurate immunization record system in Ontario, and the panel agreed that this should be a priority initiative for the province. The use of discharge summary + yellow card is a short-term recommendation for the upcoming season, and should be replaced by an electronic means of capturing nirsevimab administration data in Ontario to facilitate the tracking of both infants born during RSV season and before RSV season.) For both infants who leave the hospital without receiving nirsevimab, and those born before the RSV season, primary HCPs should be most responsible for making certain that they have an opportunity to receive nirsevimab; local Public Health Units are well suited to make certain that those who do not have a primary HCP can receive nirsevimab, through immunization clinics. For both infants who leave the hospital without receiving nirsevimab, and those born before the RSV season, primary HCPs should be most responsible for making certain that they have an opportunity to receive nirsevimab; local Public Health Units are well suited to make certain that those who do not have a primary HCP can receive nirsevimab, through immunization clinics. Policies and protocols should be developed to ensure that regardless of the birth setting or labor and delivery provider, every infant has efficient, equitable access to nirsevimab administration, and that available access routes have been clearly communicated to parents. Policies and protocols should be developed to ensure that regardless of the birth setting or labor and delivery provider, every infant has efficient, equitable access to nirsevimab administration, and that available access routes have been clearly communicated to parents. Abbreviations: HCP = Healthcare Professional, RSV = Respiratory Syncytial Virus. Supplementary Material Supplemental Material